CAMBRIDGE BIOSCIENCE CORPORATION – Trademark Portfolio
Entity Type: 03
CAMBRIDGE BIOSCIENCE CORPORATION holds 9 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 7 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 3 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include ROTACLONE and ADENOCLONE.
Showing of trademarks Trademarks
Trademark Classifications
CAMBRIDGE BIOSCIENCE CORPORATION's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does CAMBRIDGE BIOSCIENCE CORPORATION have?
CAMBRIDGE BIOSCIENCE CORPORATION has 9 U.S. trademarks filed with the USPTO. Of these, 2 registered, 7 cancelled.
What trademark classes does CAMBRIDGE BIOSCIENCE CORPORATION file in?
CAMBRIDGE BIOSCIENCE CORPORATION files trademarks across 3 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.
What are CAMBRIDGE BIOSCIENCE CORPORATION's most well-known trademarks?
CAMBRIDGE BIOSCIENCE CORPORATION's registered trademark portfolio includes well-known marks such as ROTACLONE and ADENOCLONE. These are among 2 currently registered trademarks in the portfolio.
What is CAMBRIDGE BIOSCIENCE CORPORATION's trademark registration success rate?
CAMBRIDGE BIOSCIENCE CORPORATION has a 22% trademark registration rate, with 2 out of 9 resolved applications resulting in successful registration. Currently, 0 applications are pending review.